Validation of a Bioassay for Predicting Response to Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis.
作者信息
Ho Ching-Huang, Silva Andrea A, Giles Jon T, Bathon Joan M, Solomon Daniel H, Liao Katherine P, Ho I-Cheng
机构信息
Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Columbia University College of Physicians and Surgeons and New York Presbyterian Hospital, New York, New York.
出版信息
Arthritis Rheumatol. 2021 Jun;73(6):1086-1087. doi: 10.1002/art.41645. Epub 2021 Apr 16.
Abstract
摘要
相似文献
1
Validation of a Bioassay for Predicting Response to Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis.一种预测类风湿关节炎患者对肿瘤坏死因子抑制剂反应的生物测定法的验证
Arthritis Rheumatol. 2021 Jun;73(6):1086-1087. doi: 10.1002/art.41645. Epub 2021 Apr 16.
2
Activated Peripheral Blood B Cells in Rheumatoid Arthritis and Their Relationship to Anti-Tumor Necrosis Factor Treatment and Response: A Randomized Clinical Trial of the Effects of Anti-Tumor Necrosis Factor on B Cells.类风湿关节炎中活化的外周血 B 细胞及其与抗肿瘤坏死因子治疗和应答的关系：抗肿瘤坏死因子对 B 细胞影响的随机临床试验。
Arthritis Rheumatol. 2022 Feb;74(2):200-211. doi: 10.1002/art.41941. Epub 2021 Dec 27.
3
Multiomics and Machine Learning Accurately Predict Clinical Response to Adalimumab and Etanercept Therapy in Patients With Rheumatoid Arthritis.多组学和机器学习可准确预测类风湿关节炎患者对阿达木单抗和依那西普治疗的临床反应。
Arthritis Rheumatol. 2021 Feb;73(2):212-222. doi: 10.1002/art.41516. Epub 2020 Dec 26.
4
Lack of association between a disease-susceptible single-nucleotide polymorphism, rs2230926 of , and tumour necrosis factor inhibitor therapeutic failure in Japanese patients with rheumatoid arthritis.疾病易感单核苷酸多态性（rs2230926）与日本类风湿关节炎患者肿瘤坏死因子抑制剂治疗失败之间不存在关联。
Scand J Rheumatol. 2020 May;49(3):253-255. doi: 10.1080/03009742.2020.1716992.
5
Methotrexate reduces withdrawal rates of TNF inhibitors due to ineffectiveness in rheumatoid arthritis but only in patients who are seropositive.甲氨蝶呤可降低类风湿关节炎患者中因肿瘤坏死因子抑制剂无效而导致的停药率，但仅在血清学阳性患者中有效。
Ann Rheum Dis. 2020 Nov;79(11):1516-1517. doi: 10.1136/annrheumdis-2020-217725. Epub 2020 May 28.
6
Efficacy and retention rate of adalimumab in rheumatoid arthritis and psoriatic arthritis patients after first-line etanercept failure: the FEARLESS cohort.依那西普一线治疗失败后阿达木单抗在类风湿关节炎和银屑病关节炎患者中的疗效和保留率：FEARLESS 队列研究。
Rheumatol Int. 2020 Feb;40(2):263-272. doi: 10.1007/s00296-019-04416-3. Epub 2019 Aug 21.
7
Cost-Effectiveness Analysis of Biopharmaceuticals for Treating Rheumatoid Arthritis: Infliximab, Adalimumab, and Etanercept.治疗类风湿关节炎的生物制药的成本效益分析：英夫利昔单抗、阿达木单抗和依那西普。
Biomed Res Int. 2021 Nov 28;2021:4450162. doi: 10.1155/2021/4450162. eCollection 2021.
8
Successful switching treatment of adalimumab for refractory pyoderma gangrenosum in a patient with rheumatoid arthritis with prior use of tumour necrosis factor inhibitors: A case report and review of the literature.成功切换阿达木单抗治疗类风湿关节炎合并难治性坏疽性脓皮病患者：病例报告及文献复习。
Mod Rheumatol Case Rep. 2023 Jan 3;7(1):9-13. doi: 10.1093/mrcr/rxac023.
9
Formation and clearance of TNF-TNF inhibitor complexes during TNF inhibitor treatment.TNF 抑制剂治疗过程中 TNF-TNF 抑制剂复合物的形成与清除。
Br J Pharmacol. 2024 Apr;181(8):1165-1181. doi: 10.1111/bph.16269. Epub 2023 Dec 5.
10
Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study.比较类风湿关节炎患者一线肿瘤坏死因子抑制剂与非肿瘤坏死因子抑制剂生物制剂和靶向合成药物的疗效：来自一项大型美国注册研究的结果。
Ann Rheum Dis. 2021 Jan;80(1):96-102. doi: 10.1136/annrheumdis-2020-217209. Epub 2020 Jul 21.
引用本文的文献
1
A Machine Learning Approach for Prediction of CDAI Remission with TNF Inhibitors: A Concept of Precision Medicine from the FIRST Registry.一种基于机器学习方法利用肿瘤坏死因子抑制剂预测临床疾病活动指数缓解情况：来自FIRST注册研究的精准医学概念
Rheumatol Ther. 2024 Jun;11(3):709-736. doi: 10.1007/s40744-024-00668-z. Epub 2024 Apr 18.
本文引用的文献
1
Using the Immunophenotype to Predict Response to Biologic Drugs in Rheumatoid Arthritis.利用免疫表型预测类风湿关节炎对生物药物的反应。
J Pers Med. 2019 Oct 2;9(4):46. doi: 10.3390/jpm9040046.
2
Utilizing a PTPN22 gene signature to predict response to targeted therapies in rheumatoid arthritis.利用 PTPN22 基因特征预测类风湿关节炎对靶向治疗的反应。
J Autoimmun. 2019 Jul;101:121-130. doi: 10.1016/j.jaut.2019.04.012. Epub 2019 Apr 26.
3
Prediction of Response to Targeted Treatment in Rheumatoid Arthritis.类风湿关节炎靶向治疗反应的预测
Mayo Clin Proc. 2017 Jul;92(7):1129-1143. doi: 10.1016/j.mayocp.2017.05.009.
4
Serum interleukin-6 and survivin levels predict clinical response to etanercept treatment in patients with established rheumatoid arthritis.血清白细胞介素-6和生存素水平可预测确诊类风湿关节炎患者对依那西普治疗的临床反应。
Mod Rheumatol. 2018 Jan;28(1):126-132. doi: 10.1080/14397595.2017.1317384. Epub 2017 Jun 28.
5
Association Between Pain Sensitization and Disease Activity in Patients With Rheumatoid Arthritis: A Cross-Sectional Study.类风湿关节炎患者痛觉过敏与疾病活动度的相关性：一项横断面研究。
Arthritis Care Res (Hoboken). 2018 Feb;70(2):197-204. doi: 10.1002/acr.23266.
6
Baseline CXCL10 and CXCL13 levels are predictive biomarkers for tumor necrosis factor inhibitor therapy in patients with moderate to severe rheumatoid arthritis: a pilot, prospective study.基线CXCL10和CXCL13水平是中重度类风湿关节炎患者肿瘤坏死因子抑制剂治疗的预测生物标志物：一项前瞻性试点研究。
Arthritis Res Ther. 2016 Apr 22;18:93. doi: 10.1186/s13075-016-0995-0.
7
CD8+ T Cells Specific to Apoptosis-Associated Antigens Predict the Response to Tumor Necrosis Factor Inhibitor Therapy in Rheumatoid Arthritis.凋亡相关抗原特异性CD8 + T细胞可预测类风湿关节炎患者对肿瘤坏死因子抑制剂治疗的反应。
PLoS One. 2015 Jun 10;10(6):e0128607. doi: 10.1371/journal.pone.0128607. eCollection 2015.
8
Determining the Minimally Important Difference in the Clinical Disease Activity Index for Improvement and Worsening in Early Rheumatoid Arthritis Patients.确定早期类风湿关节炎患者临床疾病活动指数改善和恶化的最小重要差异。
Arthritis Care Res (Hoboken). 2015 Oct;67(10):1345-53. doi: 10.1002/acr.22606.
Zotero 插件